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Primary localized cutaneous nodular amyloidosis is a
rare form of cutaneous amyloidosis. Amyloid ®brils
in primary localized cutaneous nodular amyloidosis
have been reported to be originated from immuno-
globulin light chains. Immunohistochemical studies
on the lesional skins of four patients with primary
localized cutaneous nodular amyloidosis demon-
strated that amyloid deposits of all cases showed a
positive reaction with the antibodies for b2-micro-
globulin and advanced glycation end products as
well as immunoglobulin light chain (k or l). No b2-
microglobulin and advanced glycation end product
immunoreactivity was found in the amyloid deposits
of other primary localized cutaneous amyloidosis
(lichen amyloidosis and macular amyloidosis).
Double immuno¯uorescence study of the lesional
skin of primary localized cutaneous nodular amyloi-
dosis showed that anti-k light chain, anti-b2-micro-
globulin and anti-advanced glycation end product
antibodies mostly reacted with the same area of
amyloid deposit. Amyloid proteins were sequentially
extracted with distilled water from one case of pri-
mary localized cutaneous nodular amyloidosis and
recovered in the ®ve water-soluble fractions (frac-
tions I±V). Immunoblot assay of amyloid ®bril
proteins demonstrated that immunoreactive poly-
peptides with anti-k light chain antibody (29 kDa)
and with anti-b2-microglobulin antibody (12 kDa)
were detected in fractions I±V, whereas immunor-
eactive polypeptide with anti-advanced glycation end
product antibody (12 kDa) was detected exclusively
in fractions III±V but not in fractions I and II. Two-
dimensional polyacrylamide gel electrophoresis
revealed that 12 kDa polypeptide in fractions I and II
was electrophoretically identical with authentic b2-
microglobulin and that b2-microglobulin in fractions
III±V was advanced glycation end product-modi®ed
b2-microglobulin with more acidic pI value. These
results indicate that b2-microglobulin is another
major component of amyloid ®brils in primary loca-
lized cutaneous nodular amyloidosis and that b2-
microglobulin in primary localized cutaneous nodu-
lar amyloidosis is partly subjected to the modi®ca-
tion of advanced glycation end product. Key words:
advanced glycation end product/amyloid ®bril/primary loca-
lized cutaneous nodular amyloidosis/b2-microglobulin. J
Invest Dermatol 118:479±484, 2002
P
rimary cutaneous nodular amyloidosis (PLCNA) is a rare
form of cutaneous amyloidosis. Previous immunohisto-
chemical studies have shown that amyloid ®brils in
PLCNA are originated from immunoglobulin light
chains (Northcutt and Vanover, 1985; Kitajima et al,
1986; Inazumi et al, 1994). Several species of molecular weights of
polypeptides have been identi®ed with biochemical analysis of
amyloid ®brils extracted from some cases of PLCNA and found to
be of kIII and lI subgroups of immunoglobulin light chain by
sequence analysis (Husby et al, 1981; Sletten et al, 1983; Kitajima et
al, 1990). They have unique amino acid residues in common,
supporting their potential in amyloidogenesis (Foss et al, 1998);
however, the mechanism by which immunoglobulin light chain
deposits in the dermis is still unclear.
Incubation of proteins with glucose leads, through the early
products such as Schiff's base and Amadri adducts, to advanced
glycation end products (AGE) (Brownlee et al, 1988). This is
referred to as the Maillard reaction. Several lines of evidence have
emphasized a potential role for AGE in the pathogenesis of diabetic
complications, aging, actinic elastosis of aged skin, and dialysis-
related amyloidosis (Brownlee et al, 1988; Miyata et al, 1993; Horie
et al, 1997; Mizutari et al, 1997). Several AGE structures, including
pyrraline (Njoroge et al, 1987), pentosidine (Sell and Monnier,
1989), and Ne-(carboxymethyl)lysine (Almed et al, 1986) have been
identi®ed. Ne-(carboxymethyl)lysine is a glycoxidation product and
a potential biomarker of carbohydrate-dependent oxidative damage
of tissue protein in vivo (Wolff and Dean, 1987), but is considered
to be also a lipid peroxidation product because it is generated from
arachidonic acid without glucose (Fu et al, 1996). It has been
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demonstrated that a protein modi®ed by lipid peroxidation
becomes resistant against multicatalytic proteases resulting in the
marked accumulation of the protein (Friguet et al, 1994).
Hemodialysis-associated amyloidosis (HAA) is a common com-
plication in long-term hemodialysis patients. Recent biochemical
and immunohistochemical studies have demonstrated that b2-
microglobulin (b2M) is a major constituent of the amyloid ®brils in
HAA (Gejyo et al, 1985; Shirahama et al, 1985; Gorevic et al, 1986).
It is well known that serum b2M level is markedly higher (usually
> 30-fold) in these patients compared with healthy individuals
(DruÈeke, 2000). It has been reported that b2M obtained from
amyloid deposits from patients with long-term hemodialysis is
subjected to the modi®cation of AGE (Miyata et al, 1993, 1996),
suggesting the potential role of AGE-modi®ed b2M in the
amyloidogenesis of HAA.
In this study, we have isolated amyloid proteins from a case of
PLCNA and found that b2M as well as immunoglobulin light chain
is a component of amyloid ®brils of PLCNA of which serum b2M
level is normal. We also found that b2M involved in amyloid ®brils
was subjected to the modi®cation of AGE. This was con®ned by
the immunohistochemical studies of lesional skins obtained from
four cases of PLCNA. This is the ®rst report concerning the
presence of AGE-modi®ed b2M in the amyloidogenesis of
PLCNA.
MATERIALS AND METHODS
Case report Case 1 was a 71 y old Japanese man who had noticed a
solitary skin nodule gradually increasing in size on the right ®rst
interdigit for 10 y. Examination revealed a ®rm, indurated nodule,
20 mm in diameter, of which the color was slightly erythematous. No
other skin nodules were found on the body. The laboratory test showed
results within the normal range. He had a polypectomy when he was
61 y old. He has hypertension and gastric ulcer, and is being treated
with anti-hypertensive drugs and an H2 blocker.
Case 2 was a 57 y old Japanese woman who had noticed multiple
asymptomatic skin nodules gradually increasing in number on the trunk
for several months. Examination revealed multiple ®rm, indurated
nodules ranging from 5 to 20 mm in diameter of which the color was
slightly erythematous. She had an operation for gastric cancer at the age
of 41 y. Laboratory abnormalities included the following: hemoglobin,
9.5 g per dl; erythrocyte sedimentation rate, 27 mm per h; elevated IgG
(2243 mg per dl) and IgE (1196 mg per dl).
Case 3 was a 59 y old Japanese man who had noticed two
asymptomatic skin nodules gradually increasing in size on the nose for
30 y. On examination, there were two nodules on the nostril rim that
were 25 3 15 mm and 16 3 10 mm in size, respectively. The slightly
red nodules had a rough surface, and consisted of several red papules in
the center. His previous medical history was unremarkable, and labora-
tory tests were within the normal ranges.
Case 4 was a 55 y old Japanese man who had noticed asymptomatic
papules gradually increasing in number on the eyelids for 4 y. On
examination, there were linear arrangements of papules on the bilateral
borders of eyelids. The rice grain size elastic papules were skin colored,
and had a shiny, smooth surface. His previous medical history was
unremarkable, and laboratory tests showed normal results.
General conditions of these four cases were good and no signs of
macroglossia or skin lesions indicative of systemic amyloidosis were
observed. Negative activities of SS-A antibody, antinuclear antibody, and
rheumatoid factor were found. No M-protein was detected in serum
immunoelectrophoresis. Bence-Jones protein was negative in condensed
urine. Serum b2M levels in all patients were normal. They have never
undergone hemodialysis.
Histology and histochemistry Biopsy was taken from the skin
nodules of these four case reports and embedded in paraf®n. Skin
sections showed amorphous and eosinophilic masses in the entire dermis.
A patchy cell in®ltration composed mainly of plasma cells and
lymphocytes was observed around blood vessels and amorphous masses.
The eosinophilic masses were stained with alkaline Congo red and
thio¯avin T, which maintained the af®nity after exposure to potassium
permanganate (Fig 1a). It also showed green birefringence under
polarized light. Electron microscopy showed straight, nonbranching
®laments of 6±7 nm in diameter deposited around or inside the collagen
®brils (not shown). On the basis of these histochemical and clinical data,
four patients were diagnosed as PLCNA.
Immunohistochemistry Immunohistochemical studies were
performed using the peroxidase±anti-peroxidase method, with anti-sera
to amyloid protein AA (monoclonal antibody, Dako, Glostrup,
Denmark), k light chain, l light chain (monoclonal antibody, Zymed
Laboratories, CA), b2M (polyclonal antibody, CosmoBio, Tokyo, Japan),
and AGE (clone no. 6D-12) (monoclonal, Kumamoto Immuno-
histochemical Laboratory, Kumamoto, Japan) (Horiuchi et al, 1991;
Ikeda et al, 1996). Skin specimens were ®xed with 10% buffered
formalin and embedded in paraf®n. Paraf®n-embedded sections were
incubated with anti-amyloid protein AA at 1:50 dilution, anti-l light
chain or anti-k light chain antibody at 1:10 dilution, anti-b2M at 1:150
dilution, or anti-AGE antibody at 1:150 dilution for 24 h, then reacted
with anti-rabbit immunoglobulin or anti-mouse immunoglobulin at
1:500 dilution for 1 h. Antigen±antibody complex was visualized with
avidin±biotin complex. For double immuno¯uorescence study, the
paraf®n-embedded sections or cryostat sections were incubated with anti-
k light chain and anti-b2M antibodies for 24 h at 1:10 and 1:150
dilutions, respectively, or with anti-b2M and anti-AGE antibodies for
24 h at 1:150 dilutions. Bound antibodies were visualized with
¯uorescence-conjugated anti-rabbit IgG (1:10) (Dako) and rhodamine-
conjugated anti-mouse IgG (1:20) (Dako). Evaluation of ¯uorescence
was performed with a confocal laser scan microscope (LSM 410, Carl
Zeiss, Jena, Germany).
Western blot analysis Skin samples were obtained from the lesional
skin of case 1 and normal appearing skin of a healthy individual
(abdominal region, 65 y old, male) as a negative control. Enough skin
samples to extract and analyze amyloid protein were not available in
cases 2±4. Amyloid ®brils were extracted with distilled water sequentially
according to the procedure of Pras et al (1968). Brie¯y, amyloid-laden
skin was homogenized with 50 mm Tris±HCl, pH 7.4 containing
0.15 m NaCl in a Virtis-45 high-speed homogenizer at 4°C for 5 min.
The homogenate was centrifuged at 10,000 3 g for 30 min at 4°C. The
supernatant was discarded and the precipitate was rehomogenized in the
same buffer. These procedures were repeated six times until the optical
density of 280 nm of the supernatant solution reached less than 0.05.
The last precipitate was homogenized with cold distilled water and
centrifuged at 10,000 3 g for 30 min at 4°C. The ®rst supernatant was
discarded and the precipitate was homogenized with distilled water
followed by a centrifugation at 30,000 3 g for 1 h at 4°C. The
supernatant solution (fraction I) was lyophilized and stored at ±80°C.
This procedure were repeated four times and corresponding supernatant
fractions were obtained (fractions II±V). The yield of the protein in each
supernatant fraction (fractions I±V) was 2, 2, 1, 2, and 1 mg per ml,
respectively. Water soluble material was dissolved with 10 mm Tris±
HCl, pH 6.8 containing 0.1% sodium dodecyl sulfate (SDS) and 0.1% b-
mercaptoethanol, and heat-denatured at 90°C for 1 min, then analyzed
by 10±20% gradient SDS±polyacrylamide gel electrophoresis (SDS±
PAGE) (Laemmli, 1970) or two-dimensional PAGE. For two-
dimensional PAGE, isoelectric focusing in the ®rst dimension was
performed in a gel column (0.13 3 6.0 cm) containing 0.4% of pH 3.5±
10 and 0.1% of pH 5.0±8.0 ampholines (Pharmacia LKB Biotechnology
Inc., Uppsala, Sweden) in the presence of 2% nonidet P40. The
electrophoresis in the second dimension was performed in a slab gel
containing a gradient 10±20% SDS±polyacrylamide. (O'Farrel, 1975).
Human serum b2M) was purchased from Sigma and used as an authentic
sample. The samples were electrophoretically transferred to nitrocellulose
membrane (Towbin et al, 1979). The membranes were incubated with
anti-l or anti-k light chain (1:10 dilution), anti-b2M (1:600 dilution) or
anti-AGE (1:400 dilution) antibodies for 1 h, then reacted with anti-
rabbit IgG (Dako) or anti-mouse IgG (Dako) at 1:600 dilution for 1 h.
Antigen±antibody was visualized by a chemiluminescence kit (Amersham
Pharmacia Biotech, Buckinghamshire, U.K.).
Electron microscopy An aliquot was taken from water-extracted
fractions I±V and then combined. The pooled proteins in fractions I±V
were subjected to electron microscopic observation by negative staining
with phosphotungustate (Shirahama and Cohen, 1967; Kitajima et al,
1986).
RESULTS
Immunohistochemical studies Amyloid deposits in cases 1±3
were positively stained with anti-k light chain antibody but not
with anti-l light chain antibody (Figs 1b, c). In case 4, amyloid
deposit reacted with anti-l light chain but not with anti-k light
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chain. There was no positive stain with anti-amyloid protein AA in
cases 1±4. Amyloid deposit in case 1 reacted with anti-b2M
antibody to the similar extent to that of anti-k light chain (Fig 1d).
In®ltrating cells around amyloid deposits consisting of plasma cells
and lymphocytes were also positive with anti-b2M antibody. Anti-
AGE antibody recognized the amyloid deposit in case 1 (Fig 1e).
Essentially similar results were obtained in the amyloid deposit of
cases 2±4. For control experiments, skin specimens from three cases
of lichen amyloidosis and ®ve cases of macular amyloidosis were
incubated with anti-b2M and anti-AGE antibodies, but showed no
positive reaction (not shown). The immunohistochemical studies
were summarized in Table I.
Double immuno¯uorescence studies The paraf®n-embedded
or cryostat sections from skin specimens were stained with both
anti-b2M and anti-AGE antibodies. Both antibodies were found to
recognize the entire area of amyloid deposition (Fig 2A). When
the sections were stained with both anti-b2M and anti-k light chain
antibodies, both antibodies mostly reacted with the same area of
amyloid deposit, but there was some area in which anti-k light
chain antibody preferentially reacted (Fig 2B).
Electron microscopic studies The mixture of water-soluble
fractions I±V showed an amyloid ®bril structure by negative
staining that composed of nonbranching and straight ®laments
(Fig 3).
Immunoblot assay One major (29 kDa) polypeptide and
several minor polypeptides with molecular weights of 150, 100,
62, 50, 43, 38, 26, 12, and 10 kDa were detected in case 1 with a
silver stain, whereas no detectable polypeptide was seen in normal
appearing skin of the healthy individual (not shown). The major
29 kDa polypeptide in fractions I±V reacted with anti-k light chain
antibody (Fig 4a). No immunoreactive polypeptide was detected
with anti-l light chain antibody (not shown). Anti-b2M antibody
Figure 2. Double immuno¯uorescence labeling
of the lesional skin of PLCNA (case 1). The
sections were stained with anti-b2M (left), anti-
AGE (middle) or both (right) antibodies (A), or
anti-b2M (left), anti-k light chain (middle) or
both (right) antibodies (B). Scale bar: 100 mm.
Figure 1. Histochemistry and immunohisto-
chemistry of amyloid deposit in the lesional
skin of PLCNA (case 1). Paraf®n-embedded
skin sections were stained with (a) Congo red, or
with the antibodies for (b) k light chain, (c) l light
chain, (d) b2M, (e) AGE Scale bars: 200 mm.
Table I. Summary of immunohistochemistry of PLCNA
and other cutaneous amyloidosisa
Case Age/sex
Immunochemistry with the antibodies for
k light chain l light chain b2M AGE
PLCNA 71/M + ± + +
57/F + ± + +
59/M + ± + +
55/M ± + + +
LA n = 3 ± ± ± ±
MA n = 5 ± ± ± ±
aLA, lichen amyloidosus; MA, macular amyloidosis; b2M, b2-microglobulin;
AGE, advanced glycation end product.
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recognized a speci®c 12 kDa polypeptide in all fractions (Fig 4b).
Anti-AGE antibody was found to immunoreact with the
polypeptide that had a molecular weight of 12 kDa in fractions
III±V, but not in fractions I and II (Fig 4c). Both anti-b2M and
anti-AGE antibodies recognized the same 12 kDa polypeptide
(Fig 4d), suggesting that b2M in fractions III±V is modi®ed with
AGE.
In order to identify the polypeptide immunoreacted with
anti-b2M antibody, immunoblot analysis after two-dimensional
electrophoresis of the proteins in fractions I and V was
performed using anti-b2M antibody. Immunoblot studies dem-
onstrated that 12 kDa polypeptide in fraction I recognized by
anti-b2M antibody has a pI value of » 6.3 (Fig 5b), which
appeared to be identical with that of authentic b2M (Fig 5a).
By contrast, 12 kDa polypeptide in fraction V recognized by
anti-b2M antibody appeared to have more acidic pI value
(» 5.5) (Fig 5c). To know the difference of pI values between
12 kDa polypeptides in fractions I and V, the mixture of
fractions I and V was further analyzed by immunoblot. Two
distinct spots with different pI values were found (Fig 5d). The
mixture of fraction V and authentic b2M also gave two spots
(Fig 5e), whereas the mixture of fraction I and authentic b2M
gave a single spot (Fig 5f), indicating that the 12 kDa
polypeptide in fraction I is identical to authentic b2M, and
the 12 kDa polypeptide in fraction V is similar to a more acidic
b2M.
When the mixture of fraction I and authentic b2M was
immunoblotted and incubated with anti-AGE antibody, no
signi®cant spot was seen (Fig 6a). The mixture of fraction V
Figure 5. Two forms of b2M are components
of amyloid ®brils in PLCNA. Authentic b2M
and the proteins in fractions I and V were
resolved on two-dimensional PAGE, then
transblotted on to membranes. The membrane
were incubated with anti-b2M antibody at 1:1000
dilution for 2 h: (a) authentic b2M; (b) the
proteins in fraction I; (c) the proteins in fraction
V; (d) the proteins in the mixture of fractions I
and V; (e) authentic b2M and the proteins in
fraction V; ( f ) authentic b2M and the proteins in
fraction I. Positive spots are indicated by arrows.
Figure 4. Immunoblotting analysis of
amyloid protein recovered in ®ve fractions.
Amyloid proteins were serially extracted with
distilled water and resolved on 10±20% gradient
SDS±PAGE. The proteins were blotted on to
nitrocellulose membranes and reacted with anti-k
light chain antibody (a), anti-b2M antibody (b),
anti-AGE antibody (c), or both anti-b2M and
anti-AGE antibodies (d). Antigen±antibody
complex was detected by chemiluminescence.
Molecular markers were indicated in the left side.
Figure 3. Water-extracted amyloid ®brils in the combined
fractions I±V as visualized by negative staining. Scale bar: 100 nm.
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and authentic b2M was found to give a single spot (Fig 6b),
indicating that b2M in fraction V but not in fraction I is
modi®ed by AGE.
DISCUSSION
Previous biochemical studies have demonstrated that amyloid ®brils
in PLCNA consisted of several species of polypeptides with
apparent molecular weights of 10 kDa or 14 kDa or 17, 20, and
29 kDa. Some of them have been sequenced and found to be of the
kIII, lI, or lIII subgroup of immunoglobulin light chains (Husby et
al, 1981; Sletten et al, 1983; Kitajima et al, 1990). Western blot
assays in case 1 of PLCNA have shown that 29 kDa polypeptide is
immunoreacted with anti-k light chain antibody but not with anti-
l light chain antibody. The result of western blot and
immunohistochemical studies are in agreement with these previous
reports that amyloid ®brils in PLCNA are derived from
immunoglobulin light chains.
It is noted that b2M is detected in the amyloid ®bril of PLCNA
by immunohistochemical and biochemical studies. It is well known
that b2M is a major component of dialysis-associated amyloidosis
(HAA). The patients with HAA mostly show a high level of b2M in
sera, and a deposition of amyloid is positive with anti-b2M
antibody (DruÈeke, 2000); however, because it has been found that
there is no statistical correlation between its serum concentration
and the occurrence of HAA (Gejyo et al, 1986a, b), the pathologic
role of b2M in HAA still remains to be determined. Present cases of
PLCNA have normal b2M levels in sera and have no history of
hemodialysis, or complications of carpal tunnel syndrome and
destructive arthropathies resulting from HAA. This suggests that
b2M deposition in PLCNA is unrelated to the serum b2M level,
but rather related to the altered metabolism of b2M in the local
cutaneous tissues. We have attempted to detect b2M in other forms
of primary cutaneous amyloidosis, lichen amyloidosis, and macular
amyloidosis in which the major component of amyloid ®brils is
considered to be keratin (Kumakiri and Hashimoto, 1979;
Kobayashi and Hashimoto, 1983), but failed to detect b2M by
immunohistochemical studies, suggesting that presence of b2M may
be restricted to the amyloid ®brils of PLCNA.
This study provided the evidence that b2M in PLCNA is
modi®ed by AGE and has a more acidic pI value than unmodi®ed
b2M. The involvement of AGE-modi®ed b2M has been reported
in amyloid ®brils of HAA. In HAA patients, AGE-modi®ed b2M is
considered to be important for the pathogenesis of HAA because it
has been reported that prolonged systemic elevation of serum b2M
level is not always an essential factor for amyloidogenesis of HAA
(Gejyo et al, 1986a, b; Miyata et al, 1993). It has been demonstrated
that a protein modi®ed by AGE becomes resistant against catalytic
proteases resulting in the accumulation of the protein in the tissues
(Friguet et al, 1994). In this regard, AGE modi®cation of b2M may
be an important pathologic event for the amyloidogenesis of
PLCNA. AGE-modi®ed b2M was detected only in fractions III±V
and not in fractions I and II. This may be because AGE-modi®ed
b2M has a different solubility from intact b2M recovered in
fractions I and II.
It is uncertain why b2M accumulates in the amyloid deposit of
PLCNA. b2M is a low molecular weight protein (Mr »11,800)
present in normal human serum. b2M has been identi®ed as the
light chain of the class I major histocompatibility antigens (HLA-A,
B, and C) that are found on the cell surface of all nucleated cells.
b2M is dissociated from the heavy chain of HLA by ``shedding'' and
appears in its free form in extracellular ¯uids, such as serum, urine,
saliva, or cerebrospinal or pleural ¯uids (Schardijn and Statius van
Eps, 1987). As the in®ltrating cells around the amyloid deposit of
PLCNA immunohistochemically showed a positive reaction with
anti-b2M antibody, these cells appear to be responsible for an
abnormal level of b2M in the lesional skin.
Amyloid deposit with mixed components of immunoglobulin
light chains and b2M has never been reported in PLCNA. The
complete amino acid sequence of b2M exhibits the striking
homology to the various homology regions CL, CH1, CH2 and
CH3 of IgG1 (Cunningham et al, 1973). The IgG-related structure
of b2M may render b2M prone to amyloid ®bril formation. The
question whether the deposition of b2M is a primary event or
secondary to the deposition of immunoglobulin light chains in
PLCNA remains to be answered; however, because a considerable
amount of b2M in fractions I±V was detected in SDS±PAGE, b2M
as well as immunoglobulin light chains appears to be a major
component of amyloid ®brils in PLCNA.
It has been reported that b2M amyloid ®brils readily depolymer-
ize into monomeric b2M from neutral to basic pH (Yamaguchi et al
2001). Because AGE-modi®ed b2M in fractions III±V of PLCNA
is more acidic than intact b2M in fractions I and II, AGE-modi®ed
b2M will be expected to more readily form insoluble amyloid ®brils
than unmodi®ed b2M. Although only amyloid ®brils of combined
fractions from I to V were observed by electron microscopy in this
study, it will be interesting to study the potential role of AGE
modi®cation in amyloid formation in PLCNA.
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